EpilepsyEPI-OPMNCT07281222
Evaluation of the FYNA Research OPM MEG Device for Locating Epileptic Foci as Part of Pre-surgical Assessment of Epilepsy
A study testing MEG OPM and MEG SQUID in people with Epilepsy, run by Hospices Civils de Lyon at 3 sites in France.
Trial summary
The success of epilepsy surgery depends largely on the reliability of the preoperative localization of the epileptogenic zone. The conventional method for determining the area to be removed is based on a complex assessment involving an electroencephalogram (EEG) coupled with simultaneous video recording of seizures… Read more about this study
- Who is it for?
- Ages 6 to 65 years
- Conditions the study is for
- Epilepsy
- What is being tested?
- MEG OPM and MEG SQUID
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 3 sitesFrance
- Study dates
- Sep 2026to Mar 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 65 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients aged 6 to 65
- Patients suffering from partial epilepsy that has been developing for at least 2 years, drug-resistant, regardless of the presumed topographical origin or suggested cause (lesional with or without MRI abnormality) and for whom the following have been decided and planned:
- either i) a surgical procedure to resect the epileptogenic zone without prior intracranial EEG recording or ii) intracranial EEG recording necessary before a possible cortical resection procedure
- Patients who have undergone routine prolonged scalp video EEG recording showing interictal paroxysmal abnormalities
- Patients motivated to participate effectively in the project
- Patients who have signed an informed consent form to participate in the study
Who cannot join
- Patients with neurological or psychiatric disorders or a history of neurological or psychiatric disorders, sleep disorders other than epilepsy that may impact the variability or quality of the data or the cooperation and retention of the participant, which will be assessed by the principal investigator or co-investigator during the inclusion interview.
- Patients with contraindications common to MEG and MRI examinations:
- Metal in the body that is incompatible with the examination (pacemaker, implanted pump including insulin pump, neurostimulator, cochlear implants or other hearing devices, metal prosthesis, intracerebral/surgical clips for aneurysms, implantable defibrillators, ferromagnetic foreign bodies in the eyes or brain in the upper body, ventriculoperitoneal neurosurgical shunt valves, dental braces or steel pivots for dental root canals, ferromagnetic foreign bodies in the upper body)
- Claustrophobia
- Pregnant women, breastfeeding women, or women who have given birth within the last 6 months.
- Patients under guardianship, curatorship, or judicial protection
- Patients deprived of their liberty
- Patients not affiliated with a social security system or beneficiaries of such a system
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
France3 sites
Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Service Explorations Fonctionnelles Pédiatriques
Bron, 69500
Zeynep GOKCE-SAMAR, MD, zeynep.gokce-samar@chu-lyon.fr
Zeynep GOKCE-SAMAR, MD
Hôpital Neurologique, Hospices Civils de Lyon, Service Explorations Fonctionnelles Neurologiques et Epileptologie
Bron, 69500
Julien JUNG, Professor, julien.jung@chu-lyon.fr
Julien JUNG, Professor
Hôpital de la Timone, AP-HM Service d'Epileptologie et Rythmologie Cérébrale
Marseille, 13005
Francesca BONINI, MD, francesca.bonini@univ-amu.fr
Francesca BONINI, MD
About this study
The success of epilepsy surgery depends largely on the reliability of the preoperative localization of the epileptogenic zone. The conventional method for determining the area to be removed is based on a complex assessment involving an electroencephalogram (EEG) coupled with simultaneous video recording of seizures (video SEEG), a brain MRI, and a fluorodeoxyglucose positron emission tomography scan (PET-FDG).
At present, epilepsy surgery cannot cure all patients. Since the prognosis for surgery depends primarily on the ability to delineate the epileptogenic zone, it is essential to develop new diagnostic approaches that can accurately detect epileptic foci.
Read more
MEG (magnetoencephalography) is a non-invasive brain mapping technique based on the magnetic fields created by neuronal activity. Numerous studies have shown that it is a highly effective technique for locating epileptic foci, and more accurate than EEG. However, MEG remains relatively uncommon (three centers in France) because current conventional systems (MEG SQUID) are difficult to use, expensive, require significant structural constraints for installation, and are not very sensitive (sensors are distant from the scalp).
Mag4Health has developed a new MEG device, the "MEG FYNA Research", which records brain magnetic activity using 48 or 96 sensors (4He optical pumping magnetometers, or "OPMs"). Compared to conventional MEG (SQUID MEG), this OPM MEG technology is more compact, less expensive, more sensitive, and allows the sensors to be placed directly on the scalp.
The EPI-OPM study is a prospective, uncontrolled, bicenter clinical investigation that aims to evaluate the diagnostic performance of this device.
The main objective is to assess the value of the OPM MEG device for localizing the epileptogenic zone compared to the reference method in epileptic patients undergoing epilepsy surgery.
Patients (children and adults) will be enrolled at the Lyon University Hospital and the Marseille University Hospital.
Each patient will undergo an OPM MEG examination and a SQUID MEG examination (SQUID MEG only for patients in Lyon), in addition to the clinical procedures performed as part of routine care: intracranial EEG recording (SEEG) and MRI if necessary, followed by surgery to resect the epileptic focus.
The performance of the OPM MEG device in locating epileptic foci will be validated by surgical results and invasive EEG recordings. The localization of epileptic foci using the OPM MEG system will be compared with that obtained using the SQUID MEG system (conventional MEG) and other pre-surgical assessment tests carried out as part of routine care. Finally, we will describe tolerance to the recordings and assess overall comfort and feasibility using appropriate questionnaires.
- Conditions
- Epilepsy
- Being tested
- MEG OPM, MEG SQUID
- Keywords
- Epilepsy, magnetoencephalography, MEG, Fyna Research, epilepsy surgery, epileptic foci
- Medical subject headings
- Epilepsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MEG OPMDevice
The OPM MEG sensor (FYNA Research device) is a new sensor technology for MEG (magnetoencephalography). It consists of 48 detectors (helium-4 magnetometers) that are positioned on the patient's head using a support system that can be adjusted to fit the size of their head. The patient goes to the MEG center at CERMEP (patients included in Lyon) or INS (patients included in Marseille), changes clothes, and removes any makeup. Metal-free clothing designed for MEG is provided. The tracking coils are put in place. The patient is then placed in the MEG, and their positioning and comfort are checked again.
The OPM MEG acquisition takes about 60 minutes.
MEG SQUIDDevice
The MEG SQUID is the classical MEG (magnetoencephalography). It consists of a set of sensors placed in a rigid helmet, in contact with the head. The patient goes to the MEG center at CERMEP (patients included in Lyon) or INS (patients included in Marseille), changes clothes, and removes any makeup. Metal-free clothing designed for MEG is provided. The tracking coils are put in place. The patient is then placed in the MEG, and their positioning and comfort are checked again.
The OPM MEG acquisition takes about 60 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Drug-resistant epilepsy patients who are candidates for epilepsy surgery | Experimental | Patients are drug-resistant epilepsy who are candidates for whom the following are decided and planned:
either 1) a surgical procedure to resect the epileptogenic zone without prior intracranial EEG recording or 2) intracranial EEG recording necessary prior to a possible cortical resection procedure They will undergo two imaging examinations specific to the study: OPM MEG examination with the FYNA Research device evaluated in this study and a conventional SQUID MEG examination. If necessary (not already performed/available), the will undergo a brain MRI during a single visit. Receives: Device: MEG OPM; Device: MEG SQUID |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of cases in which the location of epileptic foci identified by MEG OPM confirmed the location identified by pre-surgical assessment (EEG, SEEG, MRI, PET-FDG) when surgery was successful, one year after its completion (composite outcome)
To do this, the existence of a spatial overlap between the location of the epileptic focus in MEG and the area operated on in patients will be assessed.
The location of the area operated on in cured patients is considered to be the reference location of the epileptogenic zone.
For each patient included, the location of the preoperative MEG epileptic focus will be determined by source modeling applied to the detected epileptic spikes.
The area operated on will be determined on the postoperative MRI, and the success of the operation will be determined by the Engel score, which summarizes the postoperative evolution of epilepsy in terms of seizure frequency in the context of routine care.
Measured: 1 year after surgery (18 months after inclusion)
Secondary outcomes (10)
Percentage of cases in which the location of epileptic foci identified by MEG OPM differs from the location identified by conventional pre-surgical assessment (EEG, SEEG, MRI) when surgery was unsuccessful, 1 year after surgery.
To do this, the existence of a spatial overlap between the location of the epileptic focus in MEG and the area operated on in patients will be assessed.
The location of the area operated on in cured patients is considered to be the reference location of the epileptogenic zone.
For each patient included, the location of the preoperative MEG epileptic focus will be determined by source modeling applied to the detected epileptic spikes.
The area operated on will be determined on the postoperative MRI, and the success of the operation will be determined by the Engel score, which summarizes the postoperative evolution of epilepsy in terms of seizure frequency in the context of routine care.
Measured: 1 year after surgery (18 months after inclusion)
Percentage of congruence between the location of the epileptic focus determined by OPM MEG source modeling and the area of seizure onset estimated by SEEG.
For each patient included, the location of the MEG OPM epileptic focus will be determined by source modeling applied to the detected epileptic spikes.
The seizure onset zone in SEEG will be determined by analyzing the SEEG signals obtained as part of routine care.
For each patient, the spatial overlap between the area modeled in MEG and the seizure onset zone in SEEG will be determined, allowing good or poor congruence to be determined.
Measured: 3 months after inclusion (Day of the SEEG Exploration)
Percentage of congruence between the location of the epileptic focus determined by OPM MEG source modeling and the location of the epileptic focus determined by SQUID MEG source modeling.
For each patient included, the location of the epileptic focus will be determined using OPM MEG and SQUID MEG source modeling applied to the detected epileptic spikes.
For each patient, the spatial overlap between the area modeled using OPM MEG and the area modeled using SQUID MEG will be determined, allowing good or poor congruence to be identified.
Measured: Day of the MEG visit (day of inclusion)
Percentage of cases in which the location of epileptic foci identified by MEG SQUID confirmed the location identified by conventional pre-surgical assessment (EEG, SEEG, MRI) when surgery was successful, one year after its completion.
To do this, the existence of a spatial overlap between the location of the epileptic focus in MEG SQUID and the area operated on in patients will be evaluated.
The location of the area operated on in cured patients is considered to be the reference location of the epileptogenic zone.
For each patient included, the location of the epileptic focus by MEG SQUID will be determined by source modeling applied to the detected epileptic spikes.
The area operated on will be determined on the postoperative MRI, and the success of the operation will be determined by the Engel score, which summarizes the postoperative evolution of epilepsy in terms of seizure frequency in the context of routine care.
Measured: 1 year after surgery (18 months after inclusion)
Percentage of cases in which the location of epileptic foci identified by MEG SQUID confirmed the location identified by conventional pre-surgical assessment (EEG, SEEG, MRI, PET-FDG) when surgery was successful, one year after its completion.
To do this, the existence of a spatial overlap between the location of the epileptic focus in MEG SQUID and the area operated on in patients will be assessed.
The location of the area operated on in cured patients is considered to be the reference location of the epileptogenic zone.
For each patient included, the location of the epileptic focus by MEG SQUID will be determined by source modeling applied to the detected epileptic spikes.
The area operated on will be determined on the postoperative MRI, and the success of the operation will be determined by the Engel score, which summarizes the postoperative evolution of epilepsy in terms of seizure frequency in the context of routine care.
Measured: 1 year after surgery (18 months after inclusion)
Percentage of congruence between the area modeled in MEG OPM and the area of seizure onset estimated in MEG SQUID
For each patient included, the location of the epileptic focus MEG (OPM and SQUID) will be determined by source modeling applied to the detected epileptic spikes.
For each patient, the spatial overlap between the area modeled in MEG OPM and the area modeled in MEG SQUID will be determined, allowing good or poor congruence to be determined.
Measured: Day of the MEG visit (Day of inclusion)
Percentage of congruence between the location of the epileptogenic zone determined by MRI and the location modeled by OPM MEG
For each patient included, the location of the epileptic focus by MEG OPM will be determined by source modeling applied to the detected epileptic spikes.
For each patient, the spatial overlap between the area modeled in MEG OPM and the area detected on MRI will be determined, allowing good or poor congruence to be determined.
Measured: Day of the MEG visit (day of inclusion)
Proportion of congruence between the location of a hypometabolic focus in FDG PET and the location of epileptic foci modeled by MEG OPM
For each patient included, the location of the epileptic focus by MEG OPM will be determined by source modeling applied to the detected epileptic spikes.
For each patient, the spatial overlap between the area modeled by MEG OPM and the area detected by PET-FDG will be determined, allowing good or poor congruence to be determined.
Measured: Day of the MEG visit (day of inclusion)
Description of adverse events that occurred and were related to the performance of the MEG OPM examination
Description of adverse events that occurred and were related to the performance of the MEG OPM examination
Measured: From date of inclusion until the end of the study (54 months after inclusion)
Evaluation of patient comfort during OPM MEG recordings using a Likert scale
Lickert scale with 5 possible responses: very uncomfortable, uncomfortable, neutral, comfortable, very comfortable
Measured: Day of the MEG visit (day of inclusion)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Dec 2025
- Study startSep 2026 (estimated)
- Primary completionMar 2030 (estimated)
- Study completionMar 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EpilepsyStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Collaborators
- MAG4Health
- Responsible party
- Sponsor
- Investigators
- Julien JUNG, Professor, Principal investigator, Hospices Civils de LyonDenis SCHWARTZ, PhD, Study director, Institut National de la Santé Et de la Recherche Médicale, France
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07281222
- Sponsor's protocol ID
- 69HCL24_0886
- Other IDs
- 2025-A02262-47
- Acronym
- EPI-OPM
- Status last verified
- Apr 2026
- First submitted
- 20 Nov 2025
- Last updated
- 23 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the FYNA Research OPM MEG Device for Locating Epileptic Foci as Part of Pre-surgical Assessment of Epilepsy
- ClinicalTrials.gov ID
- NCT07281222
- Acronym / sponsor ID
- EPI-OPM / 69HCL24_0886
- Conditions
- Epilepsy
- Keywords
- Epilepsy, magnetoencephalography, MEG, Fyna Research, epilepsy surgery, epileptic foci
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Collaborators
- MAG4Health
- Study start
- Sep 2026 (estimated)
- Primary completion
- Mar 2030 (estimated)
- Study completion
- Mar 2030 (estimated)
- First posted
- 15 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The success of epilepsy surgery depends largely on the reliability of the preoperative localization of the epileptogenic zone. The conventional method for determining the area to be removed is based on a complex assessment involving an electroencephalogram (EEG) coupled with simultaneous video recording of seizures (video SEEG), a brain MRI, and a fluorodeoxyglucose positron emission tomography scan (PET-FDG).
At present, epilepsy surgery cannot cure all patients. Since the prognosis for surgery depends primarily on the ability to delineate the epileptogenic zone, it is essential to develop new diagnostic approaches that can accurately detect epileptic foci.
MEG (magnetoencephalography) is a non-invasive brain mapping technique based on the magnetic fields created by neuronal activity. Numerous studies have shown that it is a highly effective technique for locating epileptic foci, and more accurate than EEG. However, MEG remains relatively uncommon (three centers in France) because current conventional systems (MEG SQUID) are difficult to use, expensive, require significant structural constraints for installation, and are not very sensitive (sensors are distant from the scalp).
Mag4Health has developed a new MEG device, the "MEG FYNA Research", which records brain magnetic activity using 48 or 96 sensors (4He optical pumping magnetometers, or "OPMs"). Compared to conventional MEG (SQUID MEG), this OPM MEG technology is more compact, less expensive, more sensitive, and allows the sensors to be placed directly on the scalp.
The EPI-OPM study is a prospective, uncontrolled, bicenter clinical investigation that aims to evaluate the diagnostic performance of this device.
The main objective is to assess the value of the OPM MEG device for localizing the epileptogenic zone compared to the reference method in epileptic patients undergoing epilepsy surgery.
Patients (children and adults) will be enrolled at the Lyon University Hospital and the Marseille University Hospital.
Each patient will undergo an OPM MEG examination and a SQUID MEG examination (SQUID MEG only for patients in Lyon), in addition to the clinical procedures performed as part of routine care: intracranial EEG recording (SEEG) and MRI if necessary, followed by surgery to resect the epileptic focus.
The performance of the OPM MEG device in locating epileptic foci will be validated by surgical results and invasive EEG recordings. The localization of epileptic foci using the OPM MEG system will be compared with that obtained using the SQUID MEG system (conventional MEG) and other pre-surgical assessment tests carried out as part of routine care. Finally, we will describe tolerance to the recordings and assess overall comfort and feasibility using appropriate questionnaires.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Drug-resistant epilepsy patients who are candidates for epilepsy surgery | Experimental | Device: MEG OPM, Device: MEG SQUIDPatients are drug-resistant epilepsy who are candidates for whom the following are decided and planned: either 1) a surgical procedure to resect the epileptogenic zone without prior intracranial EEG recording or 2) intracranial EEG recording necessary prior to a possible cortical resection procedure They will undergo two imaging examinations specific to the study: OPM MEG examination with the FYNA Research device evaluated in this study and a conventional SQUID MEG examination. If necessary (not already performed/available), the will undergo a brain MRI during a single visit. |
Who may qualify
- Ages
- 6 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (6 listed)
- Patients aged 6 to 65
- Patients suffering from partial epilepsy that has been developing for at least 2 years, drug-resistant, regardless of the presumed topographical origin or suggested cause (lesional with or without MRI abnormality) and for whom the following have been decided and planned:
- either i) a surgical procedure to resect the epileptogenic zone without prior intracranial EEG recording or ii) intracranial EEG recording necessary before a possible cortical resection procedure
- Patients who have undergone routine prolonged scalp video EEG recording showing interictal paroxysmal abnormalities
- Patients motivated to participate effectively in the project
Key exclusion criteria (8 listed)
- Patients with neurological or psychiatric disorders or a history of neurological or psychiatric disorders, sleep disorders other than epilepsy that may impact the variability or quality of the data or the cooperation and retention of the participant, which will be assessed by the principal investigator or co-investigator during the inclusion interview.
- Patients with contraindications common to MEG and MRI examinations:
- Pregnant women, breastfeeding women, or women who have given birth within the last 6 months.
- Patients under guardianship, curatorship, or judicial protection
- Patients deprived of their liberty
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MEG OPMThe OPM MEG sensor (FYNA Research device) is a new sensor technology for MEG (magnetoencephalography). It consists of 48 detectors (helium-4 magnetometers) that are positioned on the patient's head using a support system that can be adjusted to fit the size of their head. The patient goes to the MEG center at CERMEP (patients included in Lyon) or INS (patients included in Marseille), changes clothes, and removes any makeup. Metal-free clothing designed for MEG is provided. The tracking coils are put in place. The patient is then placed in the MEG, and their positioning and comfort are checked again. The OPM MEG acquisition takes about 60 minutes. | Device | Drug-resistant epilepsy patients who are candidates for epilepsy surgery |
| MEG SQUIDThe MEG SQUID is the classical MEG (magnetoencephalography). It consists of a set of sensors placed in a rigid helmet, in contact with the head. The patient goes to the MEG center at CERMEP (patients included in Lyon) or INS (patients included in Marseille), changes clothes, and removes any makeup. Metal-free clothing designed for MEG is provided. The tracking coils are put in place. The patient is then placed in the MEG, and their positioning and comfort are checked again. The OPM MEG acquisition takes about 60 minutes. | Device | Drug-resistant epilepsy patients who are candidates for epilepsy surgery |
Primary outcome
Percentage of cases in which the location of epileptic foci identified by MEG OPM confirmed the location identified by pre-surgical assessment (EEG, SEEG, MRI, PET-FDG) when surgery was successful, one year after its completion (composite outcome)
Time frame: 1 year after surgery (18 months after inclusion)
To do this, the existence of a spatial overlap between the location of the epileptic focus in MEG and the area operated on in patients will be assessed. The location of the area operated on in cured patients is considered to be the reference location of the epileptogenic zone. For each patient included, the location of the preoperative MEG epileptic focus will be determined by source modeling applied to the detected epileptic spikes. The area operated on will be determined on the postoperative MRI, and the success of the operation will be determined by the Engel score, which summarizes the postoperative evolution of epilepsy in terms of seizure frequency in the context of routine care.
10 secondary outcomes
Percentage of cases in which the location of epileptic foci identified by MEG OPM differs from the location identified by conventional pre-surgical assessment (EEG, SEEG, MRI) when surgery was unsuccessful, 1 year after surgery.
Time frame: 1 year after surgery (18 months after inclusion)
Percentage of congruence between the location of the epileptic focus determined by OPM MEG source modeling and the area of seizure onset estimated by SEEG.
Time frame: 3 months after inclusion (Day of the SEEG Exploration)
Percentage of congruence between the location of the epileptic focus determined by OPM MEG source modeling and the location of the epileptic focus determined by SQUID MEG source modeling.
Time frame: Day of the MEG visit (day of inclusion)
Percentage of cases in which the location of epileptic foci identified by MEG SQUID confirmed the location identified by conventional pre-surgical assessment (EEG, SEEG, MRI) when surgery was successful, one year after its completion.
Time frame: 1 year after surgery (18 months after inclusion)
Percentage of cases in which the location of epileptic foci identified by MEG SQUID confirmed the location identified by conventional pre-surgical assessment (EEG, SEEG, MRI, PET-FDG) when surgery was successful, one year after its completion.
Time frame: 1 year after surgery (18 months after inclusion)
Percentage of congruence between the area modeled in MEG OPM and the area of seizure onset estimated in MEG SQUID
Time frame: Day of the MEG visit (Day of inclusion)
Percentage of congruence between the location of the epileptogenic zone determined by MRI and the location modeled by OPM MEG
Time frame: Day of the MEG visit (day of inclusion)
Proportion of congruence between the location of a hypometabolic focus in FDG PET and the location of epileptic foci modeled by MEG OPM
Time frame: Day of the MEG visit (day of inclusion)
Description of adverse events that occurred and were related to the performance of the MEG OPM examination
Time frame: From date of inclusion until the end of the study (54 months after inclusion)
Evaluation of patient comfort during OPM MEG recordings using a Likert scale
Time frame: Day of the MEG visit (day of inclusion)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2026.
Related trials for Epilepsy
Not yet recruiting
Clinical Trial of SEEG for Drug-resistant Epilepsy
Drug-Resistant Epilepsy
RecruitingPhase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Seizures, Lennox Gastaut Syndrome
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Focal Seizure, Epilepsy
Active, not recruitingObservational study
Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)
Traumatic Brain Injury, Post-traumatic Epilepsy
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Focal Seizure, Epilepsy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Julien JUNG, Professor principal investigator
Hospices Civils de Lyon
Denis SCHWARTZ, PhD study director
Institut National de la Santé Et de la Recherche Médicale, France
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MEG OPM and MEG SQUID in people with Epilepsy, run by Hospices Civils de Lyon at 3 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Julien JUNG, Professor (+33472357900, julien.jung@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of cases in which the location of epileptic foci identified by MEG OPM confirmed the location identified by pre-surgical assessment (EEG, SEEG, MRI, PET-FDG) when surgery was successful, one year after its completion (composite outcome) (time frame: 1 year after surgery (18 months after inclusion)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2026.